# CAMK2N2

## Overview
CAMK2N2 is a gene that encodes the protein calcium/calmodulin-dependent protein kinase II inhibitor 2, which plays a significant role in the regulation of calcium signaling pathways, particularly in the brain. This protein functions as an inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII), a pivotal enzyme involved in synaptic plasticity, learning, and memory. By modulating CaMKII activity, CAMK2N2 influences various cellular processes, including the phosphorylation of AMPA receptors, which is crucial for synaptic function and cognitive processes (Convertini2013Genome; B2022DNA). The protein is primarily active in the brain and interacts with other proteins and noncoding RNAs, suggesting its involvement in broader signaling networks, including the WNT3/β-catenin pathway (Yin2020Identification). Alterations in CAMK2N2 expression have been linked to neurological and cardiovascular conditions, highlighting its clinical significance (Convertini2013Genome; Yin2020Identification).

## Function
The CAMK2N2 gene encodes the calcium/calmodulin-dependent protein kinase II inhibitor 2, which plays a crucial role in regulating calcium signaling pathways in the brain. This protein functions as an inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII), a key enzyme involved in various cellular processes, including synaptic plasticity, learning, and memory (Convertini2013Genome; B2022DNA). By inhibiting CaMKII, CAMK2N2 modulates the phosphorylation of AMPA receptors in post-synaptic neurons, which is essential for synaptic plasticity and normal brain development (B2022DNA).

CAMK2N2 is primarily active in the brain, where it helps regulate neuronal signaling and function. It interacts with the ARHGAP32 protein, promoting GTP hydrolysis on small GTPases such as RHOA, CDC42, and RAC1, which are involved in various signaling pathways (Convertini2013Genome). The protein's activity is crucial for maintaining proper synaptic function and plasticity, which are vital for cognitive processes. Additionally, CAMK2N2 has been implicated in the regulation of the WNT3/β-catenin signaling pathway, suggesting its involvement in broader cellular signaling networks (Yin2020Identification).

## Clinical Significance
Alterations in the expression of the CAMK2N2 gene have been implicated in several neurological and cardiovascular conditions. In the context of amyotrophic lateral sclerosis (ALS), a mutation in the FUS gene, specifically the FUS-ΔNLS variant, leads to an upregulation of CAMK2N2 expression. This mutation causes an accumulation of the mutant FUS protein at the CAMK2N2 promoter, resulting in increased CAMK2N2 mRNA and protein levels, which may contribute to the pathogenesis of ALS (Convertini2013Genome).

In the realm of cognitive impairments, overexpression of CAMK2N2 in the dorsal hippocampus has been shown to impair long-term memory (LTM) formation, although it does not affect LTM maintenance. This suggests that excessive CAMK2N2 expression can disrupt normal memory processes (Vigil2017Prevention).

CAMK2N2 is also involved in essential hypertension through its interaction with noncoding RNAs. The gene is part of a regulatory network involving lncRNAs and circRNAs that modulate the WNT3/β-catenin signaling pathway. Altered expression of CAMK2N2, along with WNT3, has been associated with hypertension, potentially influencing vascular smooth muscle cell function (Yin2020Identification).

## Interactions
CAMK2N2, a calcium/calmodulin-dependent protein kinase II inhibitor, interacts with CAMKII by binding to its hydrophobic T-site, which prevents substrate access and modulates its activity. This interaction is crucial for regulating synaptic plasticity and memory processes, as CAMKII is a key enzyme in these pathways (Vigil2017Prevention). CAMK2N2 requires the presence of calcium/calmodulin to bind to CAMKII, distinguishing its interaction dynamics from other inhibitors like CaMK2N1 (Vigil2017Prevention).

The protein is also involved in a regulatory network with noncoding RNAs, such as LOC646616 and hsa_circ_0038648, which are co-expressed with CAMK2N2 mRNA. These ncRNAs share microRNA binding sites with CAMK2N2, suggesting a mechanism that influences the WNT/β-catenin signaling pathway, particularly in the context of essential hypertension (Yin2020Identification). This network highlights the potential role of CAMK2N2 in cardiovascular disease signaling pathways, although specific physical interactions with nucleic acids are not detailed (Yin2020Identification).

CAMK2N2's interaction with CAMKII and its involvement in ncRNA regulatory networks underscore its significance in modulating calcium signaling and neuronal functions.


## References


[1. (Convertini2013Genome) Paolo Convertini, Jiayu Zhang, Pierre de la Grange, Lawrence J. Hayward, Haining Zhu, and Stefan Stamm. Genome wide array analysis indicates that an amyotrophic lateral sclerosis mutation of fus causes an early increase of camk2n2 in vitro. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1832(8):1129–1135, August 2013. URL: http://dx.doi.org/10.1016/j.bbadis.2013.03.015, doi:10.1016/j.bbadis.2013.03.015. This article has 7 citations.](https://doi.org/10.1016/j.bbadis.2013.03.015)

[2. (Yin2020Identification) Liang Yin, Jie Yao, Guangxue Deng, Xuemei Wang, Weijuan Cai, and Jie Shen. Identification of candidate lncrnas and circrnas regulating wnt3/β-catenin signaling in essential hypertension. Aging, 12(9):8261–8288, May 2020. URL: http://dx.doi.org/10.18632/aging.103137, doi:10.18632/aging.103137. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.103137)

[3. (Vigil2017Prevention) Fabio Antonio Vigil, Keiko Mizuno, Walter Lucchesi, Victoria Valls-Comamala, and Karl Peter Giese. Prevention of long-term memory loss after retrieval by an endogenous camkii inhibitor. Scientific Reports, June 2017. URL: http://dx.doi.org/10.1038/s41598-017-04355-8, doi:10.1038/s41598-017-04355-8. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-017-04355-8)

[4. (B2022DNA) Kim B, Sasaki S, Murphy K, and Matthews SG. Dna methylation signatures in human neonatal blood following maternal antenatal corticosteroid treatment. Yearbook of Paediatric Endocrinology, September 2022. URL: http://dx.doi.org/10.1530/ey.19.8.3, doi:10.1530/ey.19.8.3. This article has 0 citations.](https://doi.org/10.1530/ey.19.8.3)